cabergoline has been researched along with fluvoxamine in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Higuchi, H; Sugawara, Y; Yoshida, K | 1 |
| Chiba, S; Kunugi, H; Ninomiya, M; Numakawa, T; Yoon, HS | 1 |
1 review(s) available for cabergoline and fluvoxamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for cabergoline and fluvoxamine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Dramatic remission of treatment-resistant depression after the cessation of tricyclic antidepressants.
Topics: Adult; Antidepressive Agents, Tricyclic; Cabergoline; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Female; Fluvoxamine; Humans; Imipramine; Substance Withdrawal Syndrome; Treatment Outcome | 2006 |
Cabergoline, a dopamine receptor agonist, has an antidepressant-like property and enhances brain-derived neurotrophic factor signaling.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cabergoline; Depression; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Fluvoxamine; Hippocampus; Male; Mitogen-Activated Protein Kinase 3; Rats; Rats, Inbred WKY; Rats, Wistar; Signal Transduction; Up-Regulation | 2010 |